Selcia Limited today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Ongar, Essex, United Kingdom. Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Simon Saxby is currently Vice-President Biologics of RecipharmCobra Biologics, a Swedish contract development and manufacturing company and has worldwide responsibility for the manufacturing of biologics. Simon has over 25 years experience in the biotechnology industry, including several CEO positions, most recently at Cobra Biomanufacturing plc and Alpha Biologics. He brings a blend of technical, business, sales and marketing skills and senior management, fund-raising and M&A experience.
Commenting on the appointment, Managing Director of Selcia, Dr Hans Fliri said: “I am delighted to welcome Simon to the management team. Simon brings with him his considerable international experience, technical knowledge and commercial expertise. We look forward to Simon helping us accelerate our UK and international market development plans”.